Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)

Koen A van Overdam; Jerry Sebag

doi:10.1016/j.ophtha.2023.02.022

Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)

Vitreoretinal surgery

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	e21
Journal	Ophthalmology
Volume	130
Issue number	6
DOIs	https://doi.org/10.1016/j.ophtha.2023.02.022
Publication status	Published - Jun 2023

Access to Document

10.1016/j.ophtha.2023.02.022

Cite this

@article{05aeab3d81a5425e885d822ca98374e7,

title = "Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)",

author = "{van Overdam}, {Koen A} and Jerry Sebag",

year = "2023",

month = jun,

doi = "10.1016/j.ophtha.2023.02.022",

language = "English",

volume = "130",

pages = "e21",

number = "6",

}

TY - JOUR

T1 - Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)

AU - van Overdam, Koen A

AU - Sebag, Jerry

PY - 2023/6

Y1 - 2023/6

UR - https://www.mendeley.com/catalogue/62fe78fe-7b54-3b65-8291-76de88a8f727/

U2 - 10.1016/j.ophtha.2023.02.022

DO - 10.1016/j.ophtha.2023.02.022

M3 - Comment/debate

C2 - 37210149

SN - 0161-6420

VL - 130

SP - e21

JO - Ophthalmology

JF - Ophthalmology

IS - 6

ER -

Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)

Access to Document

Other files and links

Cite this